Nectar Lifesciences Ltd
Nectar Lifesciences Ltd (NECLIFE) last reported results for the quarter ended Jun 2026, with sales of ₹0 crore and net profit of ₹-15 crore. The stock last traded at ₹10.6, a market capitalisation of ₹205 crore. Over the past 52 weeks the stock has ranged between ₹9.2 and ₹22.5. Figures are as of 6 Oct 2026 and are not real time.
Nectar Lifesciences Ltd share price and key metrics
- Current price
- ₹10.6
- Market cap
- ₹205 cr
- Book value
- ₹30
- ROE
- -31.3%
- ROCE
- 0.05%
- Dividend yield
- 0.00%
- 52w high / low
- 22.5/9.20
Metrics as of 6 Oct 2026. Not real time.
Track Nectar Lifesciences Ltd
Cruxal reads every Nectar Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Nectar Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -78%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -9161%
- 10 Years
- -12%
- 5 Years
- -20%
- 3 Years
- -24%
- 1 Year
- -27%
- 10 Years
- -3%
- 5 Years
- -8%
- 3 Years
- -12%
- Last Year
- -31%
Nectar Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0 cr, down 100.0% from ₹5 cr a year earlier. Net profit was ₹-15 cr, up 76.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 |
| Expenses | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 |
| Operating profit | -1 | -0 | -0 | -1 | 1 | -2 | -57 | -27 |
| OPM % | -10% | -500% | -500% | -16% | 77% | — | -4,437% | -6,198% |
| Other income | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 |
| Depreciation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit before tax | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 |
| Tax % | -2% | 2% | -0% | -1% | 0% | -339% | -22% | -37% |
| Net profit | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 |
| EPS (₹) | 0.25 | 0.35 | -5.80 | -2.82 | -7.85 | 0.64 | -3.50 | -0.79 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Nectar Lifesciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 1,664 | 0 | 2 |
| Operating profit | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | -30 | -8 | -86 |
| OPM % | 14% | 13% | 10% | 9% | 7% | 10% | 3.5% | 9% | -1.8% | -2,920% | -3,520% |
| Net profit | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -245 |
| EPS (₹) | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 | -11.50 |
TTM is the trailing twelve months to the most recent quarter.
Nectar Lifesciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| Reserves | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 |
| Borrowings | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 |
| Other liabilities | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 |
| Total liabilities | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
| Fixed assets | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 |
| CWIP | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 |
| Investments | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 |
| Other assets | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 |
| Total assets | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 |
As reported by the company. Total assets equal total liabilities by construction.
Nectar Lifesciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | -349 |
| Cash from investing | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Cash from financing | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| Net cash flow | -23 | -4 | 12 | -0 | 4 | -8 | -0 | 2 | -1 | 93 |
| Free cash flow | 174 | 32 | 204 | 249 | -10 | 110 | 183 | 195 | 126 | -341 |
| CFO / operating profit | 92% | 33% | 96% | 134% | 23% | 60% | 252% | 148% | -574% | 4,132% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Nectar Lifesciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 10% | 9% | 10% | 8% | 3% | 5% | -0% | 6% | -5% | 0% |
| Debtor days | 112 | 119 | 73 | 61 | 89 | 98 | 67 | 82 | 76 | — |
| Inventory days | 270 | 226 | 151 | 192 | 185 | 197 | 212 | 215 | 184 | — |
| Days payable | 167 | 142 | 80 | 104 | 108 | 112 | 100 | 127 | 117 | — |
| Cash conversion cycle | 215 | 203 | 145 | 150 | 166 | 182 | 179 | 170 | 143 | — |
| Working capital days | 45 | 67 | 46 | 53 | 6 | 73 | 77 | 63 | 43 | — |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Nectar Lifesciences Ltd shareholding pattern
Promoters held 51.84% at Jun 2026, up from 44.53% at Jun 2025. FIIs 0.50% and DIIs 0.01%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 55.80% | 44.53% | 44.53% | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% |
| FIIs | 3.24% | 0.73% | 1.65% | 0.82% | 0.62% | 0.52% | 0.60% | 0.50% |
| DIIs | 0.00% | 0.00% | 0.15% | 0.19% | 0.08% | 0.00% | 0.01% | 0.01% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 5.84% | 4.03% | 3.75% |
| Public | 40.94% | 54.72% | 53.64% | 54.45% | 54.37% | 48.73% | 43.52% | 43.90% |
| No. of shareholders | 66,741 | 69,482 | 69,241 | 71,977 | 76,470 | 78,124 | 74,834 | 73,834 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Nectar Lifesciences Ltd corporate filings
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Company Updatelow impact
Cruxal's analysis: Please find attached herewith certificate as per caption regulations
Read the full analysis - Nectar Lifesciences Ltd. Holds 31st AGM; Approves Financials, Board Reappointments, and Director Appointments via ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Nectar Lifesciences Ltd. conducted its 31st AGM on September 18, 2026, through VC/OAVM…
Read the full analysis - Nectar Lifesciences files disclosure under Regulation 30; no financial or operational updates providedCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd has submitted a regulatory disclosure as per SEBI Regulation 30…
Read the full analysis - Trading window closure pursuant to SEBI ( Prohibition of Insider Trading) Regulations, 2015Insider Trading / SASTlow impact
- Nectar Lifesciences Ltd. Files Revised Proceedings of 31st Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has issued a revised disclosure regarding the proceedings of its…
Read the full analysis - Nectar Lifesciences Ltd. concludes 31st AGM; approves financial statements and board appointmentsAGM/EGMlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has successfully concluded its 31st Annual General Meeting held…
Read the full analysis - Nectar Lifesciences Ltd. Concludes 31st Annual General Meeting with Routine Board Re-appointmentsAGM/EGMlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has successfully concluded its 31st Annual General Meeting held…
Read the full analysis - Nectar Lifesciences Ltd issues statutory notice to members under SEBI LODR Regulation 36(1)(b)Company Updatelow impact
Cruxal's analysis: Nectar Lifesciences has issued a formal communication to its members in compliance with…
Read the full analysis - Nectar Lifesciences announces 31st Annual General Meeting and book closure datesCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences has published a newspaper notice regarding its 31st Annual General…
Read the full analysis - Nectar Lifesciences Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Nectar Lifesciences has submitted its Annual Report for the financial year ended March…
Read the full analysis - Nectar Lifesciences Ltd. Announces 31st Annual General Meeting (AGM) for September 18, 2026AGM/EGMlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has issued a notice for its 31st Annual General Meeting (AGM) to…
Read the full analysis - Nectar Lifesciences Ltd. Announces 31st Annual General Meeting Scheduled for September 18, 2026Company Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has issued a formal notice regarding its 31st Annual General…
Read the full analysis - Nectar Lifesciences Reports Q1 FY2027 Financial Results with Continued Operational LossesCompany Updatehigh impact
Cruxal's analysis: Nectar Lifesciences Limited has released its financial results for the quarter ended June…
Read the full analysis - Nectar Lifesciences Ltd announces change in corporate office addressCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd has filed a routine disclosure regarding a change in its…
Read the full analysis - Nectar Lifesciences Ltd. Announces Book Closure Dates for 31st Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has formally notified the stock exchanges regarding the closure…
Read the full analysis - Nectar Lifesciences reports Q1 FY27 losses amid business restructuring and asset monetizationResultmedium impact
Cruxal's analysis: Nectar Lifesciences Limited reported a consolidated net loss of 15.40 crore for the…
Read the full analysis - Nectar Lifesciences Ltd. schedules Board Meeting for August 14, 2026, to approve Q1 FY2027 financial resultsBoard Meetinglow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has formally notified the stock exchanges of a board meeting…
Read the full analysis - Nectar Lifesciences Ltd. Announces Resignation of Non-Executive Non-Independent DirectorCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences Ltd. has informed the stock exchanges that Dr. Surulichamy…
Read the full analysis - Nectar Lifesciences Ltd announces sale and surrender of leasehold rights for land in JammuCompany Updatelow impact
Cruxal's analysis: Nectar Lifesciences has formally notified the exchange regarding the sale and surrender…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.